Moexipril

• Description:

  Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride) . Moexipril exhibits antihypertensive and neuroprotective effects[1]-[4].

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H312-H332

• Target:

  Angiotensin-converting Enzyme (ACE) ; Apoptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/moexipril.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=C(OC)C(OC)=C3)C1)O

• Molecular Formula:

  C27H34N2O7

• Molecular Weight:

  498.57

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

• References & Citations:

  [1]Chrysant, S.G. and G.S. Chrysant, Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol, 2004. 44 (8) : p. 827-36.|[2]Friehe H, et al. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneimittelforschung. 1997 Feb. 47 (2) :132-44.|[3]Edling O, et al. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275 (2) :854-63.|[4]Ravati A, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373 (1) :21-33.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [103775-10-6]